All News

PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels were linked to worse outcomes.

Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.

During the holiday season, overwhelming feelings are OK to have, whether you are a patient with cancer or a caregiver.

The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.

CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with cancer are at risk for.

New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS.

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.

Treatment with Columvi showed a manageable safety profile in heavily pre-treated patients with relapsed or refractory mantle cell lymphoma.

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be discontinued.

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.

As a four-time cancer survivor, I can tell you that survivorship means many things to each survivor.

An expert explained how circulating tumor cell count can identify possible clinical trial participants.

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference.

Three nurses—Maria Hicinbothem, Wandaris Ortiz, and Sandi Wetherbee—are being celebrated for their exceptional dedication to patient care, safety and advocacy.

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated approval of Dato-DXd.

When I was diagnosed with colon cancer, I had a hard time deciding what my legacy should be, but once I realized what it was, I had to keep working hard for it.

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.

Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

From producer Quincy Jones’ death from pancreatic cancer to an inspiring moment between The Rock and a fan at a store, here’s what’s happening in the cancer space this week.

In patients with oropharyngeal cancer, deciding whether radiation therapy or surgery is the best option depends on their lifestyle and their values.

Patients with glioblastoma experienced tumor control after complete in-situ vaccination and anti-PD-1 immunotherapy, researchers have reported.

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved relapse-free survival.

I spent my life racing against time, until my cancer diagnosis forced me to hit the brakes.

The advantages and disadvantages of CAR-T cell therapy should be carefully thought about for patients with melanoma.

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA.

In patients with advanced NSCLC, treatment with Jemperli plus chemotherapy showed promising effectiveness compared with Keytruda plus chemotherapy.

An expert explains how attitudes towards lymphedema risk have evolved over the years.